Open source information on cannabinoids in health and disease Heureka, our new website is online! Our team has been working hard to optimize user experience, design, internationality and content. Let us know what you think! And thank you for your feedback and patience in case of bugs and errors – We will fix them asap. …
Käfer Dachgarten-Restaurant im Deutschen Bundestag Demnächst steht in Deutschland mit dem HAPA medical Vollspektrum Cannabis Extrakt THC2.5 CBD2.5 (Lösung) ein neues Extrakt zur Herstellung eines Rezepturarzneimittels aus medizinischem Cannabis zur Verfügung. Daher laden wir Journalisten der medizinischen Fachpresse herzlich zur Launch-Fachpresseveranstaltung ein: Aus Cannabis wird Medizin – Neues orales Cannabis Extrakt THC2,5:CBD2,5 (Lösung) Montag, 12. …
Ricardo P. Victorio CEO Ricardo Pendón Victorio Mr Ricardo Pendón is the founding Managing Director of HAPA Medical. Ricardo has been a successful entrepreneur for over 15 years. He has built two companies in the health insurance and public & investor relations sector and has achieved successful exits of these businesses. He has bootstrapped the …
Our Vision We want all European patients to have access to the full therapeutic potential of phytocannabinoids. We will support continuative research on all substances of the cannabis plant and will assist to understand medical mechanisms of cannabinoids and terpenes even better in the future. We are certain that we can create multiple effective pharmaceuticals …
HAPA medical partners with Australian Zelda Therapeutics for the advancement of clinical cannabinoid research While experimental studies have already unveiled many mechanisms of action for a wide array of cannabinoids, there is still a lack of proper clinical trials which hinders the practical therapeutic application of cannabinoid medicine. Our partner Zelda Therapeutics brings together some …
HAPA Medical is an international company focused on the research, development and distribution of cannabinoid-containing drug formulations. We stand for a controlled cultivation of cannabis plants in the EU as well as for the own production of prescription medicines according to EU-GMP-guidelines.
